MedTrace Logo

Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors

NCT00003125 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2011-03-24

No results posted yet for this study

Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Combining vaccine therapy, sargramostim, and interleukin-2 may kill more cancer cells.

PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy, sargramostim, and interleukin-2 in treating patients who have advanced tumors.

Conditions

Interventions

BIOLOGICAL

ALVAC-CEA vaccine

BIOLOGICAL

aldesleukin

BIOLOGICAL

sargramostim

BIOLOGICAL

vaccinia-CEA vaccine

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Georgetown University

    lead OTHER

Principal Investigators

  • John L. Marshall, MD · Lombardi Comprehensive Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-01-31
Primary Completion
2004-11-30
Completion
2004-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003125 on ClinicalTrials.gov